Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc/ CA05156V1022 /
AUPH
|
2024-07-26 10:00:00 PM
|
Chg.
+0.0800
|
Volume |
Bid1:44:40 AM |
Ask1:44:40 AM |
High |
Low |
|
5.6800USD
|
+1.43%
|
1.01 mill.
Turnover: 4.95 mill. |
5.5700Bid Size: 200 |
5.7300Ask Size: 500 |
5.7000 |
5.5900 |
Business description
Aurinia Pharmaceuticals Inc. develops and commercializes therapies for diseases with unmet medical needs. Its product, LUPKYNIS, treats active lupus nephritis. Headquartered in Victoria, Canada, it collaborates with Otsuka Pharmaceutical Co., Ltd.
Management board & Supervisory board
| CEO |
| Peter Greenleaf |
| Management board |
| Joe Miller, Max Donley , Sue Evans, Scott Habig, Volker Knappertz, Michael Martin , Stephen Robertson |
| Supervisory board |
| R. Hector MacKay-Dunn, Jill Leversage, Jeffrey A. Bailey, Brinda Balakrishnan, Daniel G. Billen, Dr. Robert T. Foster, Peter Greenleaf, David R.w. Jayne, Dr. Karen Smith |
Company data
| Name: |
Aurinia Pharmaceuticals Inc. |
| Address: |
#140, 14315 – 118 Avenue,Edmonton, AB T5L 4S6 |
| Phone: |
+1-250-744-2487 |
| Fax: |
+1-250-708-4345 |
| E-mail: |
-
|
| Internet: |
https://www.auriniapharma.com/ |
| Industry: |
Healthcare |
| Sector: |
Pharmaceutical Industry |
| Sub sector: |
Pharmaceuticals |
| End of financial year: |
12-31 |
| Free Float: |
92.79% |
| IPO date: |
- |
Company calendar
|
CW 31 | 2024-08-01
Interim Report 2nd Quarter/6 Months
|
